

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hansen, et al.

Confirmation No.: 2043

Application No.: 09/142,326

Group Art Unit: 1631

Filing Date: January 27, 1999

Examiner: Michael L. Borin

**For: Admixture Comprising a Target Molecule and a Nucleic Acid Mimic
Comprising Sterically Bulky Substituents**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicant-Initiated Interview Summary

Date of Interview: June 9, 2008

Interview Type: ☐ Personal ☒ Telephonic ☐ Electronic Mail ☐ Video Conference ☐ Other:

Participants:

From PTO: (Include Name and Title)

1. Marjorie A. Moran, Supervisory Patent Examiner
- 2.
- 3.

For Applicant:

1. John A. Harrelson, Jr., Attorney
2. , choose one: Applicant, Attorney, Agent
3. , choose one: Applicant, Attorney, Agent
4. , choose one: Applicant, Attorney, Agent

☐ An exhibit or demonstration was included and is described below:

The claims discussed included: Claim(s)

The ☐ art ☐ prior art discussed included:

An agreement ☐ was ☐ was not reached.

☐ It was agreed that the attached claims are allowable.

☐ It was agreed that the attached amendment would be entered.

☒ The interview is summarized below.

An error in the previously submitted terminal disclaimer to copending application No. 08/612,661 was discussed. The previously submitted terminal disclaimer inadvertently listed Isis Pharmaceuticals as the owner. The owner should have been listed as Peter Nielsen. It was decided that one option for dealing with the error was for Applicants to file a replacement terminal disclaimer listing the correct owner.

Date: July 14, 2008

/John A. Harrelson, Jr./
John A. Harrelson, Jr., PhD
Registration No. 42,637

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439